AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01571440 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 12 g soluble corn fiber
Description: Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
Study NCT02151890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H\&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
Study NCT01587430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose ARA-C
Description: high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
Study NCT00390806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYCAMTIN, oral capsules
Description: topotecan oral capsules 1.1 mg/m2
Study NCT01587430 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard dose ARA-C
Study NCT03707470 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom fitted compression garments (CF)
Description: Custom fitted compression garments (Isobar, Manchester, UK) designed to provide 35 mmHg at the ankle and >20 mmHg at the mid-thigh (equivalent to European class 2 compression garments)
Study NCT03707470 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard-sized compression garments (SSG)
Description: Off-the-shelf, standard-sized garments (2XU, Campbelltown, Australia), typically providing pressures equivalent to European grade 1 compression or below (5 - 10 mmHg at both the ankle and thigh)
Study NCT03707470 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham ultrasound (CON)
Description: Sham ultrasound using an unplugged machine. Sham treatment for 5 minutes on each of the thighs, calves and hamstrings
Study NCT02255370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
Study NCT00390806 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Whole brain radiation
Study NCT00390806 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Whole brain radiation
Study NCT03180125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Description: median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound
Study NCT03180125 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ultrasound
Description: ultrasound guided injection
Study NCT03180125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound guided injection
Study NCT03180125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Hyaluronate and 1% lidocain
Description: injection in the carpal tunnel
Study NCT03180125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate and 1% lidocain
Description: injection in the carpal tunnel
Study NCT03180125 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid and 1%lidocain
Description: injection in the carpal tunnel
Study NCT02745028 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Monosodium glutamate
Description: A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
Study NCT03228212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CONTROL
Description: ACUVUE OASYS
Study NCT03228212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEST
Description: senofilcon A with new UV blocker
Study NCT02255370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Curcumin
Description: subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
Study NCT02177682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afuresertib
Description: Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
Study NCT04519281 — intervention group
Intervention type: DRUG
Intervention: IV of vitamin C
Description: administration of high-dose of IV vitamin C perioperatively
Study NCT00338923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HO/03/03
Study NCT01043991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Study NCT03231111 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventive Multimedia Teaching Program
Description: Preventive Multimedia Teaching Program
Study NCT04343157 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cognitive Sparing Brain Stereotactic Radiosurgery (SRS)
Description: In this proposal, the investigators introduce advanced diffusion and volumetric imaging techniques along with innovative, automated image parcellation methods to identify critical brain regions, incorporate into cognitive-sparing SRS, and analyze biomarkers of radiation response. This work will advance the investigators' understanding of neurocognitive changes after brain SRS and help create interventions that preserve cognitive-function in brain metastases patients.
Study NCT01043991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04606160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Session Problem-Solving Intervention
Description: The intervention will be a researcher led 30-45 minute session using the problem-solving module from the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Issues (MATCH-ADTC protocol.
Study NCT03492034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IUD during CS
Description: IUD insertion during CS
Study NCT03492034 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IUD after puerperium
Description: IUD after puerperium
Study NCT02069119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-108459
Study NCT02069119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03849222 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Apexification
Study NCT03849222 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apexification
Study NCT03849222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Study NCT03849222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTA
Study NCT03849222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ca(OH)2
Study NCT03849222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ca(OH)2
Study NCT03849222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apical matrix
Description: collagen membrane (Biocollagen; Bioteck:Turin, Italy)
Study NCT03563196 — intervention group
Intervention type: RADIATION
Intervention: Chest Radiograph
Description: Chest radiogram will be obtained on day 1
Study NCT03563196 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung Ultrasound
Description: Lung ultrasound will be done on day 1
Study NCT03123016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast
Description: Apremilast 30 mg orally, twice daily. (oral tablet)
Study NCT03123016 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NB-UVB phototherapy
Description: treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
Study NCT02489188 — intervention group
Intervention type: PROCEDURE
Intervention: arthroplasty
Description: patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery
Study NCT02489188 — intervention group
Intervention type: OTHER
Intervention: manual therapy
Description: patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
Study NCT02720692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Study NCT02720692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Study NCT01740401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
Study NCT03841435 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Radiotherapy Treatment, totaling 15 Gy, will be given in 3 fractions over 2 weeks.
Study NCT00742716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTA018 Injection
Description: Comparison of different dosages of drug
Study NCT01105273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: On days -3 to -1
Study NCT01105273 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Beginning on day 4 and continuing until blood counts recover
Study NCT01105273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/M2 once daily IV on days -6 to -2
Study NCT01105273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV on day-3 and -2
Study NCT01105273 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD3±CD19 depleted hematopoietic stem cell transplantation
Description: Immunogenetic depletion on CliniMACS
Study NCT03807414 — intervention group
Intervention type: DEVICE
Intervention: oXiris
Description: Every center will prescribe EBPT with oXiris in accordance with local practice and local levels of expertise. No variation in treatment prescription and/or treatment solutions will derive from participation in this prospective observational study. Nonetheless, every setting parameter will be recorded in the web-based registry and analyzed a-posteriori to reveal a potential correlation with the patient outcomes.
Study NCT04153045 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Radiograph interpretation for pulmonary abnormalities
Description: The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis.
Study NCT04153045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiograph interpretation for pulmonary abnormalities
Description: The pulmonary abnormalities detected by xrAI and included in the definition of abnormality are as follows: any linear scar or fibrosis, atelectasis, consolidation, abscess or cavity, nodule, pleural effusion, severe cases of emphysema and COPD (mild cases with hyperinflation but not significant emphysema are not flagged), pneumothorax.~Participants in the treatment group will interpret 500 images presented alongside the results of xrAI's processing in a dark room and asked to categorize each image into one of the following categories: lungs are clear, at least one pulmonary abnormality is present, not sure.~Participants in the control group will be asked to interpret the same 500 images as the treatment group but without xrAI's analysis.
Study NCT06158191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification program
Description: Participants will take part in a lifestyle modification program focused on physical activity and diet.
Study NCT01213979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg iron isomaltoside 1000
Description: 500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
Study NCT01213979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1000 mg iron isomaltoside 1000
Description: 1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
Study NCT02891707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)
Description: The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation.
Study NCT00952107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLARE imaging system
Description: Testing of operation of imaging system
Study NCT01817725 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV vaccine (Engerix B)
Description: Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those \<= 20 years old and 40μg in those > 20 years old.
Study NCT02857452 — intervention group
Intervention type: OTHER
Intervention: SLA Questionnaire
Study NCT02857452 — intervention group
Intervention type: OTHER
Intervention: Lupus Qol Questionnaire
Study NCT03179397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model SC9
Description: Experimental
Study NCT03179397 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Model LI61SE
Description: Active Comparator
Study NCT02489188 — intervention group
Intervention type: PROCEDURE
Intervention: lumbar spinal stenosis decompression
Description: patients, who are scheduled for lumbar spinal stenosis decompression, will be measured before and on average 6 months after surgery
Study NCT03487211 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily
Study NCT05716126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]Iruplinalkib (WX-0593)
Description: Volunteer will receive a single oral dose of 120 mg \[14C\]Iruplinalkib (WX-0593) as a solution on Day 1
Study NCT03654833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: PARP inhibitor
Study NCT03487211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily
Study NCT03261453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Elipse Device
Description: Intervention Device
Study NCT03261453 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Elipse Sham Device
Description: Control Device
Study NCT03654833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: CDK4/6 inhibitor
Study NCT03654833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab & bemcentinib
Description: PD1 checkpoint inhibitor, AXL inhibitor
Study NCT03654833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab & Bevacizumab
Description: PDL1 checkpoint inhibitor, VEGF inhibitor
Study NCT02453503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licorice
Description: licorice mucoadhesive films evey 6 hours for two weeks
Study NCT02453503 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
Study NCT02737345 — intervention group
Intervention type: OTHER
Intervention: Rotem
Study NCT01835665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimodipine
Description: Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
Study NCT03654833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab and Niraparib
Description: IG Antibody, PARP Inhibitor
Study NCT00556868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breakfast/no breakfast
Description: A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.~B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention
Study NCT02610946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic application
Description: Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
Study NCT02610946 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Paper-based
Description: Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
Study NCT04406077 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ligasure
Description: Using ligasure to treat hydrocele
Study NCT01790074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TrP therapy
Description: TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
Study NCT01790074 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TrP manual control therapy
Description: The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
Study NCT05681598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: The treatment started with a dose of 15mg/kg/day of HU. This initial dose was increased in steps of 5mg/kg/day every three months up to 35mg/kg/day or a maximal tolerated dose.
Study NCT03073876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: 5mg of Donepezil Hydrochloride by mouth
Study NCT03073876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: 5mg of Donepezil Hydrochloride by mouth
Study NCT03073876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
Study NCT02726659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Adjunct celecoxib
Study NCT01629459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise and protein supplementation
Description: Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
Study NCT04764227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw\*5
Study NCT04764227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=2, ivgtt, d1, qw\*5
Study NCT04764227 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 1.8Gy/d, d1-5/week, 28Fx
Study NCT02726659 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Adjunct placebo
Study NCT03347201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HMS Plus
Description: Subjects randomized to the intervention group will have their dose of Heparin and Protamine calculated by the HMS Plus.
Study NCT00079716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-40 (anti-huCD40 mAb)
Description: 0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
Study NCT00358436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
Study NCT00358436 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks